All Life

In 2015, the United Nations adopted the 2030 Agenda for Sustainable Development, which is comprised of 17 Sustainable Development Goals (SDGs). SDG 3 targets good health and well-being, with the goal of improving global health outcomes. There has been notable progress in achieving this goal with several important health strides addressing SDG3. This includes the reduction of global AIDS-related deaths by 52% since 2010 and the elimination of at least one neglected tropical disease in 47 countries.

Even considering the progress made to address global health, the human population as a whole still continues to face threats including infectious disease (ID) and non-communicable diseases (NCD). In ID, new malaria cases have surged since 2019, with the number of worldwide cases reaching almost 250 million. NCD including cardiovascular diseases, cancer, chronic respiratory diseases and diabetes, kill 41 million people each year, equivalent to 74% of all deaths globally. According to the World Health Organization, 2022 saw approximately 20 million new cancer diagnoses and 9.7 million cancer-related deaths. The number of children missing routine immunizations has increased since 2019. These are examples of continuous health issues that place SDG3, and more importantly, the global population at risk.

In this Article Collection, All Life addresses SDG3: Good Health and Well-Being through innovative open scientific research that can be used to further our knowledge of various threats to human health under the sections “Biochemistry, Cell, and Molecular Biology”, “Cancer Biology”, “Translational physiology” and “Microbiology”. This Article Collection will accept original research articles, reviews, short communications, data notes, and commentaries on topics including, but not limited to:

1. Vector-borne pathogens,
2. Current and innovative treatments to reduce antibiotic resistance
3. Immune response to pathogens and self-antigens, vaccines and allergic reactions
4. Early plasma biomarkers for early predicting diabetes complications, cardiovascular diseases and chronic respiratory diseases
5. New strategies for battling chemoresistance in cancers and advances in chemotherapy and radiotherapy.
6. Understanding cancer tissue growth and potential carcinogenic agents
7. Plasma biomarkers for early cancer diagnosis and targets for treatment
8. Pathophysiology of organs in ID and NCD

---

­­All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisor for this Collection will not be handling the manuscripts (unless they are an Editorial Board member).

Please review the journal scope and author submission instructions prior to submitting a manuscript.

The deadline for submitting manuscripts is March 28, 2025.

Please contact Ashley Ambros at [email protected] with any queries and discount codes regarding this Article Collection.

Please be sure to select the appropriate Article Collection from the drop-down menu in the submission system, and please select "Biochemistry, Cell, and Molecular Biology", "Cancer Biology", or "Microbiology" from the list of available sections during submission. Failure to select the appropriate Article Collection or Section name can result in delays.

---

Dr. Amar ABDERRAHMANI (AA) is Full Professor of Cell and Molecular Biology at the Faculty of Medicine at Lille University. He is currently the head of the team devoted to nanomaterials for health in the institute of electronics, microelectronics and nanotechnologies. He has a multidisciplinary background including a PhD and Pharmacy Graduation in Molecular Genetics and Pharmaceutical Chemistry. AA has been honored by several Swiss awards and in 2011, of National Chair of Excellence in beta-cell biology, bioscience and diabetes. AA has been a member of several scientific committees of the Diabetes Association.

Instructions for AuthorsSubmit an Article